<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2248836&amp;fmt=gif">
MIM Software Inc.
 

MIM Software Inc.

MIM SurePlan™ MRT and MIM SurePlan™ LiverY90

Stand out in Theranostics

Stand out in Theranostics

Standardized Dosimetry Workflows Overcome the Trade-Offs Between Quality and Efficiency

Conventional approaches to dosimetry rely on outdated methods that don’t scale and lead to inefficiencies that departments won’t tolerate as demand for therapies continues to grow. These outmoded methods further widen the gap that Nuclear Medicine departments face as they seek to adopt theranostics – putting them even further behind the curve.

Nuclear Medicine Departments are Changing

A Shift to Theranostics Presents Unique Challenges

Nuclear Medicine Departments are Changing - A Shift to Theranostics Presents Unique Challenges

Current and Future Nuclear Theranostic Approaches1

 
Nuclear Theranostic Pair Target Application
68Ga- and 177Lu-DOTATATE Somatostatin receptors NETs
68Ga- and 177Lu-PSMA PSMA Prostate cancer
123I- and 131I-iobenguane Norepinephrine reuptake transporter Neuroblastoma, paraganglioma, pheochromocytoma
68Ga- and 177Lu-FAPI Fibroblast activation protein Multiple cancers
68Ga- and 177Lu-3BP-227 NTR1 antagonist Neurotensin receptor 1 Pancreatic cancer
124I- and 131I-girentuximab Carbonic anhydrase 9 Renal cell cancer
123I- and 131I-iodine Sodium/iodide symporter Thyroid diseases

 

Complex Dosimetry Workflows

Homegrown solutions lack efficiency and require hospitals to create and maintain quality management systems to meet the directives. Vendors that require multiple modules make purchasing and maintenance a budgetary issue over time.

Lack of Standardization

Lack of standardization leads to inconsistent case reviews, introduces risk that an ineffective plan could slip through review, and prevents structured data from being captured.

Increase in Therapies

Lutathera treats a rare disease, and the expected volumes reflect this. Future approaches, such as PSMA therapy, present a much larger opportunity2.

MIM SurePlan™ MRT

Advancing Molecular Radiotherapy

Calculating patient-specific dose doesn’t need to add significant time to your workflow. MIM SurePlan MRT provides effective dosimetry, organ and tumor segmentation, deformable registration, and communication tools that help reduce clinical effort — all in a single solution.

MIM SurePlan™ MRT

Timesaving Tools

Automated segmentation can significantly reduce the time required to generate organ volumes, such as the kidneys and liver. Industry-leading PET and SPECT segmentation tools are available for tumors and other volumes of interest (VOIs).

Multi-Tracer Theranostics Support

Multiple Molecular Radiotherapy tracers, such as Lu-177 dotatate, I-131 mlBG, [I-131] NAI for thyroid, and more can be imaged with MIM SurePlan MRT, providing confirmation of dose delivery in the patient.

Quantitative SPECT and Planar Corrections

Vendor-neutral quantitative SPECT reconstruction is available for dosimetry in SPECTRA Quant™. Now, clinicians can generate quantitative images BASED off the imaging so dose can be measured as opposed to measuring the amount of activity.

deformable

Compare PET, SPECT, CT, MRI, and CBCT within MIM SurePlan MRT’s intuitive interface. Multi-modality rigid and deformable fusion ensure consistency when there are differences in position, size, and organ movement.

voxel-based dosimetry_

MIM SurePlan MRT provides voxel-based absorbed dose calculation using the patient’s own anatomy. Calculate isodose curves/DVH on SPECT using voxel S-value scheme in MIRD Pamphlet No.17. MIM SurePlan MRT’s automated tools for serial exam comparison make therapy response evaluation viable.

 

Supply more dosimetric information to referring physicians using the integrated reporting solution with images and statistics. Dictated text can be pulled into reports from PowerScribe® 360 and exported to PDF or DICOM structured reports.

Additional Resources

See how the experts are using dosimetry and radionuclide therapies in the clinic.

 

MIM SurePlan™ LiverY90

A Comprehensive Solution for Y90

MIM SurePlan LiverY90 provides timesaving tools for MAA dose planning*, liver and tumor segmentation, deformable registration, and post-treatment dosimetry using Y90-PET and Bremsstrahlung SPECT.

 

MIM SurePlan LiverY90™

MAA Dose Planning*

Use MAA images for planning therapies to predict Y90 doses with voxel based dosimetry and model-based formulas (Partition Model, BSA, and MIRD single compartment).

*MAA Dosimetry for MIM SurePlan LiverY90 is not commercially available in all countries. Due to regulatory reasons, its future availability cannot be guaranteed.

Timesaving Tools

MIM SurePlan LiverY90 is specifically engineered for Y90, making efficiency a top priority. A recent study3 in the Journal of Nuclear Medicine demonstrated a 70% reduction in time compared to manual outlining of the liver.

Post-Op Dosimetry

Calculate dose using Y90-PET and Bremsstrahlung SPECT. Calculate isodose curves/DVH on PET/SPECT using Local Disposition Method or MIRD Kernal.

Additional Resources

See how the experts are using MIM SurePlan LiverY90 in the clinic.

 

Footnotes

  1. Czernin, Johannes, et al., "The Future of Nuclear Medicine as an Independent Specialty." Journal of Nuclear Medicine 60, no. 2 (2019): 3S-12S.
  2. Begum, Nusrat J, et al., "The Effect of Total Tumor Volume on the Biologically Effective Dose to Tumor and Kidneys for 177Lu-Labeled PSMA Peptides." Journal of Nuclear Medicine 59, no. 6 (2018): 929–33.
  3. M Horvat, et al., Time Savings of a Multi-Atlas Approach for Liver Segmentation. Journal of Nuclear Medicine 55, no.1 (2014): 1523.

MIM Software

Learn how MIM is Improving Personalized Dosimetry

Schedule a Meeting
MIM Software Inc.

Copyright © 2024 MIM Software Inc. All Rights Reserved.